Weight-loss company Noom has acquired 503A pharmacy Tailor Made Compounding, according to an April 1 press release.
Noom Tailor Made Compounding is a 503A pharmacy that provides sterile and non-sterile compounding through its pharmacy practice focused on aging. It offers compounded drugs, including hormone replacement therapies and peptide therapies, as well as pharmacist-formulated supplements and cosmetics. The company works in men’s and women’s health, weight management, anti-aging and IV therapy, and touts a customer base of more than 400 clinics and numerous telehealth partners. It also has a compounding facility that is more than 40,000 square feet, located in Kentucky.
Founded in 2008, Noom is an American privately held digital health company that provides weight management and behavioral health services through a subscription-based mobile application. The company combines behavior change psychology with access to weight loss medications and dietary supplements.
According to Noom, the acquisition of Tailor Made will expand the range of clinically appropriate therapies available to Noom members within its leading behavior change programs and enable expansion into conditions beyond weight health.
Tailor Made will continue operating as a wholly owned subsidiary under its current leadership. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, there have been three Specialty Pharmacy acquisitions announced since the start of the year. Other deals in the space this year include Cigna’s acquisition of CarepathRx and CS One’s acquisition of Partners Pharmacy Services. There were 23 Specialty Pharmacy transactions announced in 2025, and 28 announced in 2024.
